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Uptake and accumulation of 
Microcystin-LR based on exposure 
through drinking water: An animal 
model assessing the human health 
risk
Brett Greer, Julie P. Meneely & Christopher T. Elliott
Harmful Algal Blooms (HABs) in freshwater systems and intensified aquaculture have increased the risk 
to human health through exposure to cyanotoxins such as microcystin-LR (MC-LR). To understand the 
uptake and processing of MC-LR in humans, the pig was chosen as an animal model. This was assessed 
by repeated exposure for 13 weeks of eight animals dosed daily with MC-LR at 0.04 µg/kg bw, repeated 
with six animals over five weeks at a dose 50 times higher at 2 µg/kg bw. An analytical method was 
developed for MC-LR in porcine serum and also to analyse levels of free MC-LR in harvested porcine 
tissues, with Lemieux Oxidation employed to determine bound MC-LR in these tissues. MC-LR was not 
detected in the serum of treated animals from either experiment but free MC-LR was observed in the 
large intestine and kidney from two animals from the higher dosed group at levels of 1.4 and 1.9 µg/
kg dry weight (dw) respectively. The results indicated 50% of higher dosed animals accumulated bound 
MC-LR in liver tissue, averaging 26.4 µg, approximately 1.1% of the dose administered. These results 
point to the potential uptake and accumulation of MC-LR in human liver tissue exposed chronically to 
sub-acute doses.
Harmful Algal Blooms (HABs) are increasing in number and severity in freshwater systems globally with these 
HABs caused by certain cyanobacterial species growing exponentially and producing secondary metabolites 
called cyanotoxins. Rises in HABs is in part caused by intensive use of freshwater resources such as lakes and 
reservoirs as well as pollution of these, resulting in increases in nutrients in the water which can favour cyano-
bacterial species over ‘true’ algal species1–3. Rising global temperatures caused by climate change is predicted to 
play an increasing role in the future4, with higher water temperatures known to promote surface-forming HABs.
Approximately 40 cyanobacterial species are capable of producing cyanotoxins5,6 with the most studied being 
the hepatotoxic microcystins (MCs), of which around 130 different congeners have been characterised7. MCs 
are cyclic heptapeptides, with most structural variations coming from differences in amino acids at positions 2 
and 4 within the main cyclic body of the molecule. Microcystin-LR (MC-LR), with amino acids leucine (L) and 
arginine (R) at positions 2 and 4 respectively8, is the most studied and acutely toxic and is listed as one of the most 
important algal toxins in the United States9.
MCs are toxic to humans and animals8 with one incident leading to human fatalities in Caruaru, Brazil, 
when dialysis patients were acutely exposed10. Exposure to cyanotoxins occurs when HABs release toxins 
such as MCs into their surroundings. Often the watercourse is a source of drinking water and 80% of human 
exposure is thought to result from ingestion of contaminated drinking water11, with recreational exposure also 
documented12,13. Further exposure is through consumption of contaminated food, with studies showing the bio-
accumulation of cyanotoxins including MCs in freshwater seafood14,15, with this route more than likely underes-
timated, especially with rises in aquaculture16,17.
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Due to its toxicity and based on the No Observable Adverse Effect Level (NOAEL) value of 40 µg/kg body 
weight in the 13 week drinking water study carried out in mice with MC-LR (Fawell et al. 1994), the World 
Health Organisation (WHO) established a 1 µg/L (free plus cell-bound) guideline value for drinking water and a 
Tolerable Daily Intake (TDI) of 0.04 µg/kg body weight per day for MC-LR in contaminated seafood11.
MCs primary target organ is the liver with their main mechanism of action being induction of liver failure 
by inhibition of protein phosphatases type 1 and 2A (PP1 and PP2A) in hepatocytes18. Their transportation and 
uptake into the liver through the bile acid transport system is mediated through organic anion-transporting 
polypeptides (OATPS) which are expressed in hepatocytes19. However, OATPs are known to be expressed in 
other organs such as the stomach, small and large intestines, kidney and brain20, intimating that MCs could target 
other organs. There is evidence suggesting MCs are genotoxic due to their ability to damage DNA and promote 
tumours21,22, with them also considered tumour initiators23. A correlation has been drawn between high levels 
of primary liver cancer (PLC) in regions of South East Asia and China and the drinking of surface water where 
cyanotoxins are reported to be abundant as opposed to well water21, and in 2010 MC-LR was classified as being 
possibly carcinogenic to humans24. Recent studies suggest that MC-LR may promote the migration and invasion 
of colorectal cancer and it has been implicated in renal-function impairment25,26. MC-LR has also been shown 
to cause apoptosis and changes to the permeability of the mitochondrial membrane in mice27 and can cause sup-
pression of haematopoiesis function in mice leading to normocytic anaemia through prolonged exposure28. To 
date, the only human study looking at daily exposure and subsequent health effects of chronic exposure to MCs 
was conducted by Chen et al. (2009). They identified MCs in the serum of fishermen, most likely from exposure 
to ingesting MCs from the water and fish they consumed, and showed certain enzymes linked to liver function 
were elevated in their serum, indicating hepatocellular damage29.
As discussed previously, MCs can bioaccumulate in tissues and do this as free or bound (masked) through their 
conjugation to PP1 and PP2A in certain tissues. Binding of MCs to protein phosphatases is irreversible and they 
cannot be detected by conventional extraction techniques which deal solely with extraction of free MCs. Instead, 
use of Lemieux oxidation, known to produce 2-methyl-3-methoxy-4-phenylbutyric acid (MMPB) through oxi-
dation of the Adda side chain common to every MC congener30, allows identification of bound MC.
In addition to detection of free and bound MCs, metabolites formed during detoxification of MCs in the liver 
may also be analysed. The major pathway in depuration of MCs in mammals and aquatic organisms is formation 
of conjugates such as that formed with glutathione (GSH), MC-LR-GSH (Fig. 1)31–33. This analyte is known to be 
formed in the liver as part of the detoxification process and has also been detected in the kidney of fish, although 
at lower levels than in liver31,33,34.
Although various epidemiological studies have been conducted on chronic exposure to MCs through inges-
tion of contaminated drinking water and their link to PLC35–42, there have yet to be any conclusive studies show-
ing the effects of chronic exposure to MCs apart from that conducted by Chen et al. (2009) which indicated 
hepatocellular damage. To accurately assess the damage caused by chronic exposure to MCs in humans, toxico-
logical studies are required, however this cannot be the case. In order to assess the human risk to cyanotoxins 
such as MC-LR through consumption of drinking water contaminated with these requires both epidemiological 
and toxicological studies, with the most detailed research on cyanotoxin toxicology to date having been evaluated 
in rodents43. To extrapolate from mouse to human toxicity, particularly through the use of intraperitoneal injec-
tion, requires assumptions that may not be strictly accurate, as are those studies conducted in other vertebrates 
such as sheep, cattle and rats. In order to obtain reliable data for the risk to humans from consumption of contam-
inated water, we need to study the oral ingestion of these toxins, with this previously conducted in mice to derive 
the safety guideline concentrations. However, it has been indicated that the mouse has a higher sensitivity to the 
effects of such toxins43. Therefore, in the experiments conducted herein, the pig has been used as the experimental 
model due to its gastrointestinal tract, liver and kidney functions being similar to humans. Furthermore, the body 
weight of mature pigs as well as their metabolic rates is similar to humans44,45.
The aim of this research was to use the pig as a model to study the effects of subchronic exposure to MC-LR 
through oral gavage over a period of time, carried out at both the TDI of 0.04 µg/kg bw per day and at 2 µg/kg 
Figure 1. Structure of the microcystin-LR-glutathione conjugate (MC-LR-GSH) showing conjugation between 
the thiol group of GSH to the unsaturated carbonyl moiety Mdha of MC-LR. The figure also shows the Adda 
side-chain, common to all MC congeners and responsible for the molecules toxicity.
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3ScIentIFIc REPORTS |  (2018) 8:4913  | DOI:10.1038/s41598-018-23312-7
bw per day, 50 times the TDI. The objectives of this were to: a) develop and validate a UPLC-MS/MS method for 
analysis of free MC-LR in porcine serum; b) analyse the level of free and bound MC-LR in six porcine tissues using 
UPLC-MS/MS; c) screen for the depuration product, MC-LR-GSH in specific tissues and d) assess the uptake and 
processing of MC-LR in serum and various tissues.
Results
Method Validation of MC-LR in porcine serum. The method was fully validated to EC Directive 
2002/657 for detection and quantification of MC-LR (See Supplementary information online). As the MC-LR 
used in the validation was not a Certified Reference Material (CRM) and as the MC-LR may not act as it does in 
a real sample, EC directive 2002/657 states that at the spiking level used of 5 ppb (5 ng/ml serum), the minimum 
trueness has to be in the range −30% to +10%. Taking this into account, the resulting validation showed the 
method to be fit for purpose, showing the trueness to be within the range stipulated with a value of −0.8%. The 
CCα and CCβ values were based on the less intense qualifying ion (q) and with an injection volume of 2.5 µL, the 
mean on-column CCα and CCβ values are 0.075 and 0.1 pg (ppt) respectively (Table 1).
Sample analysis: Experiment 1. Porcine serum: free MC-LR. Analysis of the pre-bleed serum (day 7) 
from the eight control and eight treated animals (n = 16) was found to be free from MC-LR. Extraction and 
analysis of the serum from all time points for the eight treated animals (n = 104) was subsequently performed, 
the results of which showed that no MC-LR was found at the detection limit of the method of 0.03 ng/mL serum.
Porcine liver tissue: free MC-LR and MC-LR-GSH. With no MC-LR detected in the serum from any of the eight 
treated animals, it was decided to also test the liver, kidney, large and small intestine tissues from the eight treated 
animals for free MC-LR in experiment (1). Initially, a sample of liver, kidney, large and small intestine tissues 
from the eight control animals were screened for free MC-LR and found to be absent of the toxin as expected. The 
liver, kidney, large and small intestine tissues from the eight treated animals were then extracted and analysed, the 
results of which showed that none of the tissues contained any trace of free MC-LR.
The liver and kidney tissues from the eight treated animals were then screened for the depuration product, 
MC-LR-GSH, with both of these tissues negative for MC-LR-GSH.
Porcine tissue: bound MC-LR. Liver tissue from each of the eight treated animals was screened for bound MC-LR 
(MMPB) using Lemieux Oxidation, the results of which showed that the livers from the eight treated animals 
were negative for MMPB and therefore any bound MC-LR.
Sample analysis: Experiment 2. Porcine serum: free MC-LR. Extraction and analysis of serum for each 
time point from the six treated animals, including pre-bleeds from the control and treated animals (n = 42), was 
performed and assayed alongside a seven point extracted matrix matched calibration curve in the range 0.2–100 
ng/mL for determination of any MC-LR detected. As with experiment (1), all pre-bleed serum samples from the 
control and treated animals were negative for MC-LR. More importantly, serum from each time point from the 
six treated animals proved to be negative for free MC-LR at the LOD of the method.
With MC-LR and its congeners, as well as any potential metabolites of MC-LR having in common the shared 
Adda group ((2S, 3S, 8S, 9S)-3-amino-9-methoxy-2, 6, 8-trimethyl-10-phenyldeca-4(E), 6(E)-dienoic acid) 
(Fig. 1)8, serum samples were analysed for parent ions of Adda, with this fragment having an m/z of 135. This was 
optimised using the MC-LR standard and indicated a peak at the same retention time as when analysed in MRM 
mode, with the retention window extended to allow identification of any potential MC-LR metabolites.
A selection of serum sample time points from experiment (1) were chosen (n = 32), with; t = 14, t = 42, t = 70 
and t = 98 correlating to the start, one, two and three months of treatment for each animal, as well as serum from 
all time points (n = 36) for each animal from experiment (2). These all proved negative for any peaks in the reten-
tion window scanned, with no peak seen at the retention time of MC-LR, further confirming the samples to be 
negative for free MC-LR and not indicating the presence of any MC-LR metabolites.
Porcine tissue: free MC-LR and MC-LR-GSH. All tissues harvested from the treated animals in Experiment (2) 
were tested for free MC-LR which included; liver, kidney, small and large intestine, spleen and brain. Tissues 
from the six treated animals were extracted and analysed (n = 36), the results of which showed two samples with 
Fortified Porcine Serum 5 ng/mL
Intra-day RSD (%) (n = 7) 3.8
Inter-day RSD (%) (n = 20) 3.8
Average conc. (repeatability) (ng/mL) 5.2
Average conc. (reproducibility) (ng/mL) 5.2
Absolute recovery (%)* 85.1
CCα (ng/mL) 0.03
CCβ (ng/mL) 0.04
Table 1. Validation data for free MC-LR in porcine serum. *Absolute recovery expressed as extraction 
efficiency when spiked at 1.25 ng toxin per 250 µL serum, equating to 5 ng/mL.
www.nature.com/scientificreports/
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measureable amounts of MC-LR, one in the kidney from treated animal 1 (T1) at 1.9 ng/g dw and one in the large 
intestine from treated animal 5 (T5) at 1.4 ng/g dw, with the chromatograms shown in Fig. 2. All other tissue sam-
ples analysed were found to be free of MC-LR residues. This is the first report of MC-LR in the tissues of pigs fed 
MC-LR through oral gavage and supports the findings of other studies, albeit in fish living in freshwater bodies 
with HABs, which indicated MC-LR in organs other than in the liver46–48.
Liver and kidney tissues from the six treated animals were also screened for the depuration product, 
MC-LR-GSH (See Supplementary information online). The results of this analysis indicated that four (66%) of 
the treated livers contained MC-LR-GSH, whereas only two (33%) of the kidneys from the six treated animals 
contained this compound. As this work was qualitative only, no concentrations could be assigned, however the 
levels detected in the liver appeared higher than those in the kidney based on the raw peak area of the quantifying 
ion, Q.
Porcine tissue: bound MC-LR. Porcine tissues from the six treated animals were initially screened for bound 
MC-LR (MMPB) using Lemieux Oxidation, with MMPB and therefore MC-LR identified in the livers of three 
treated animals: T2, T4 and T5 (Fig. 3). These were subsequently quantified with the concentrations of MMPB 
detected ranging from 11.0 to 19.1 ng/g dw, and an average estimated value of 14.4 ng/g dw. On converting the 
amount of MMPB observed to molar equivalents of MC-LR, and taking into the account the oxidation conversion 
efficiency of 83% calculated on the day of extraction, the estimated level of MC-LR detected in the livers ranged 
from 52.4 to 90.9 ng/g dw. Accounting for losses due to incomplete oxidative conversion and calculating back to 
molar equivalents of MC-LR, the levels detected in the livers ranged from 63.1 to 109.5 ng/g dw.
In must be noted that the water content of porcine liver is approximately 72% (http://slism.com/calo-
rie/111166/) and therefore to achieve a more accurate result for the levels detected, a factor of 0.28 is used to 
convert from dry weight (dw) to wet weight (ww). On doing so, the estimated levels detected were 17.7 to 30.7 
ng/g ww with an average estimated value of 23.2 ng/g ww. Taking the final weight of each pig positive for bound 
MC-LR and assuming the liver weighs approximately 2% of the total bodyweight49, the estimated amount of 
MC-LR which accumulated in each liver equated to 23.1, 21.9 and 34.1 µg for pigs T2, T4 and T5 respectively. 
With the total dose administered to each animal over the study period known, the percentage uptake and accu-
mulation of MC-LR by each liver can be calculated. This showed the percentage uptake of MC-LR by treated 
animals T2, T4 and T5 to be 1.1, 0.8 and 1.5% respectively (Table 2), with the average uptake being 1.1% of the 
total dose administered.
Discussion
A UPLC-MS/MS method was developed and validated for the extraction and analysis of free MC-LR in porcine 
serum, showing a method detection limit (CCα) of 0.03 ng/mL. The detection limit of the method is an improve-
ment to that used by Chen et al. (2009), being over 100 times more sensitive, and with their study requiring in the 
Figure 2. Ultra-high performance liquid chromatography-tandem mass spectrometry analysis of free MC-LR 
in animal tissues. Chromatograms showing samples positive for free MC-LR in (a) large intestine of animal T5 
and (b) kidney of animal T1. (MRM, multiple reaction monitoring).
www.nature.com/scientificreports/
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region of 5 mL of serum, compared to only 250 µL used in the present study, this is an important improvement in 
the methodology. A further UPLC-MS/MS method was developed for the extraction and analysis of free MC-LR 
across six porcine tissues to allow a detailed study of toxin distribution to take place.
In experiment (1), eight treated animals were dosed with MC-LR daily for 98 days at the WHO TDI value of 
0.04 µg/kg bw50. No evidence of MC-LR being present at or above the detection limit of the method (0.03 ng/mL 
serum) was found in the serum or in any of the tissues tested. The study was then repeated over a shorter time 
scale (35 days) with fewer animals (n = 6) due the costs associated with the toxin, however, this time they were 
dosed with MC-LR daily at a level of 2 µg/kg bw, 50 times above the WHO TDI. Again, no evidence of MC-LR in 
the serum of any of the treated animals was found.
Looking at the study by Tencalla et al. (1997) in which rainbow trout were dosed with MC-LR also via oral 
gavage, they estimated the uptake of MC-LR into blood to be approximately 4.4% of the dose administered of 
5700 µg MC-LR/kg bw51. Based on the findings reported by Tencalla et al. and taking the average bodyweight of 
the six animals in the final week of dosing in experiment (2) of our study, the average dose administered to the six 
animals equates to 96 µg of MC-LR per day for the last week. Before being euthanized, the average weight of the 
six animals was 58 kg, with the animals therefore having an approximate blood volume of 3.77 L (65 mL/kg bw) 
and an average estimated MC-LR concentration of 25.5 ng/mL in their blood. Based on this concentration, and 
with the Tencalla study seeing 4.4% of the oral dose administered in the blood of the rainbow trout, an approx-
imate concentration of 1 ng/mL should have been present in the serum of the animals from our study. With 
the LOD (CCα) of our method being 0.03 ng/mL, this indicates that MC-LR should have been detectable in the 
serum, however as reported, no free MC-LR was detected in the serum from any of the treated animals. This may 
however be due to the dose administered in our experiment being significantly lower, approximately 3 000 times 
less, than that given to the rainbow trout by Tencalla et al. as well as it being a different species51.
A study conducted by Chen et al. on fishermen living beside and subsisting on a lake with HABs showed MCs 
(-RR, -YR, and -LR) in the serum of the fishermen, with the proportions of the MC congeners identified in their 
serum matching those found in the fish they were consuming, rather than from the water29. This appears to imply 
that consumption of contaminated seafood as opposed to ingestion of contaminated drinking water as being the 
main route of uptake for these toxins16. The majority (77%) of these fishermen lived on the lake for more than 10 
years, with their exposure estimated around 2.2–3.9 µg MC-LR equivalents daily, making this chronic long term 
exposure as opposed to the shorter time frame used in our experiment.
Figure 3. Results of the MMPB detected in the livers from treated pigs from experiment 2 (high dose). Graph 
shows the amount of MMPB detected, the conversion to molar equivalents of MC-LR and the final estimated 
value after converting to wet weight.  Concentration of MMPB detected in porcine liver tissue using Lemieux 
Oxidation.  Molar conversion of MMPB to MC-LR and corrected for loses due to incomplete oxidation based 
on the oxidation conversion efficiency found on the day of extraction and analysis.  Conversion of 
concentration detected to wet weight (ww) from dry weight (dw) using a conversion factor of 0.28 based on 
porcine liver containing approximately 72% water.
Pig
Dose 
(µg)
Pig weight1 
(kg)
Liver 
weight2 (kg)
MC-LR conc. 
(µg/kg ww)
MC-LR 
present3 (µg)
Uptake 
(%)
T2 2191.0 54.5 1.09 21.2 23.1 1.1
T4 2667.0 62.0 1.24 17.7 21.9 0.8
T5 2240.0 55.5 1.11 30.7 34.1 1.5
Table 2. Total dose administered to the three treated animals positive for MC-LR from experiment 2. Table 
indicates the levels detected in each liver and the resulting uptake of MC-LR expressed as a percentage of the 
dose administered. 1Weight of pig at end of experiment. 2Liver weight calculated as being ~2% of the total 
bodyweight49. 3Estimated level of toxin present based on amount of MMPB detected and based on weight of 
liver at end of experiment.
www.nature.com/scientificreports/
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Another factor to consider is that MC-LR appears to be absorbed from the gastrointestinal tract into blood 
rapidly and is then quickly transported to the liver, with the liver indicating the presence of MC-LR after 1 h 
and with maximum levels at 3 h after exposure, with a half-life in the blood of 3.3 h51. In another experiment 
conducted by Robinson et al. (1991) using radiolabelled MC-LR to track its distribution in mice, levels of radio-
labelled MC-LR peaked in the liver after only 30 min52, although in this case the mice were injected intravenously 
via the tail vein rather than by oral gavage. Nevertheless, it appears that transport through the intestinal tract into 
the bloodstream and to the liver occurs rapidly, indicating the possibility that a high proportion of the MC-LR 
administered could have been cleared from the blood by the time it was collected from the pigs. Also, with the 
toxin administered through oral gavage in water may be more readily available, which may aid its transport to 
and subsequent clearance from the bloodstream, whereas being present in food may slow this process down as the 
toxin has to be released from the matrix it is present in before being processed.
Furthermore, the metabolism of MC-LR in the human gastrointestinal tract has not been fully investigated. A 
report by the WHO in 1999 indicated no evidence of hydrolysis of MCs by peptidases in the stomach, with a sig-
nificant amount of what had been ingested being absorbed53. However, as MC-LR is a cyclic heptapeptide, there 
may be the potential for proteolytic degradation of the toxin as it is processed through the gastrointestinal tract, 
with a study by Moreno and co-workers (2004) demonstrating degradation of several MCs including MC-LR 
in the gastric phase of digestion in vitro54. The transit of MC-LR through the intestinal tract was confirmed by 
the presence of free MC-LR at a level of 1.4 ng/g dw (0.29 ng/g ww) in the large intestine of treated animal T5 in 
experiment (2) of our study. The identification of MC-LR in the large intestine indicates it may accumulate in this 
tissue, with other studies in fish showing higher levels of MCs in the large intestine than in other tissues in certain 
species, which may inhibit its transport to other organs such as the liver48.
In the second experiment (high dose), with the animals dosed at 50 times above the WHO TDI at 2 µg MC-LR/
kg bw per day, all tissues harvested were analysed for both free MC-LR and total MC-LR (free plus bound). The 
results of these analyses failed to show the presence of free MC-LR, apart from the kidney of treated animal 1 (T1) 
and large intestine from treated animal 5 (T5), with levels detected of 1.9 and 1.4 ng/g dw, or 0.4 and 0.29 ng/g 
ww respectively.
Analysis of the tissues for bound MC-LR revealed 50% of livers from the treated animals in the higher dosed 
experiment were positive for bound MC-LR, with estimated levels of 23.1, 21.9 and 34.1 µg for pigs T2, T4 and T5 
respectively (Table 2), averaging 26.4 ± 5.5 µg of MC-LR. These results are the first reporting of bound MC-LR in 
pigs, confirming the uptake and binding of this toxin to proteins in the liver after exposure. Based on the average 
total dose administered to pigs T2, T4 and T5 of 2 366 µg MC-LR, and indicating an average percentage uptake 
of 1.1%, this study shows approximately 50% less uptake than that reported by Tencalla et al. (1997), with their 
study indicating 1.7% uptake of MC-LR into the liver when administered via oral gavage, albeit in rainbow trout.
One of the major depuration products in detoxifying MC-LR is MC-LR-GSH, with Kondo et al. (1996) iden-
tifying its presence in mice and rat livers, and Pflugmacher et al. (1998) indicating its formation in the liver as the 
first stage in the detoxification of MCs32,33. MC-LR-GSH is then further biotransformed to a cysteine conjugate, 
MC-LR-Cys, detected in the kidneys, presumably for excretion via the urine55. With this in mind, liver and kidney 
tissues from the treated animals of both experiments were screened for MC-LR-GSH, a qualitative analysis simi-
lar to previous studies32,33,55. The results demonstrated the presence of MC-LR-GSH in approximately 66% of the 
livers and 33% of the kidneys in animals from experiment (2) only. The levels detected in liver were higher than in 
the kidney (based on raw peak area), with these results similar to other published studies34,56.
Furthermore, Falconer et al. (1994) conducted an experiment in pigs whereby the animals were dosed orally 
at concentrations of 1 312, 796 and 280 µg/kg bw, 656, 398 and 140 times respectively higher than that used in 
experiment (2) of our study. They did not analyse serum or liver tissue for MC-LR (free or bound), but the results 
of plasma liver enzyme analyses indicated liver injury. These results support the findings of this study where 
bound MC-LR was detected in liver tissue.
The two pig studies as an animal model for humans indicates MC-LR may be processed from the blood rapidly 
due to none being detected in serum from any of the treated animals. Some is potentially metabolised as it passes 
through the gastrointestinal tract and so less may be readily available for uptake into the bloodstream, with this 
study showing free MC-LR in the large intestine, with free MC-LR also detected in the kidney. The major finding 
of this study is of bound MC-LR in the livers, with analysis of liver tissue revealing 50% of pigs from the higher 
dose experiment accumulated MC-LR.
Overall, these findings indicate uptake and accumulation of MC-LR in the liver through sublethal, chronic 
exposure, and with the pig being a suitable animal model for humans, indicates the possible accumulation in 
human livers exposed in a similar manner. Further experiments need to be conducted to further probe the link 
between chronic sub-acute exposure and long term health effects such as PLC.
Materials and Methods
Animal Experiment. Animal Study 1. The animal studies were performed under licence (PPL 2755 - 
Chemical contaminants in food producing animals) issued by the Department of Health, Social Services and 
Public Safety in Northern Ireland (NI) in accordance with the Animal (Scientific Procedures) Act (1986), and 
under the approval of the Agri-Food and Biosciences Institute (AFBI) Animal Welfare and Ethical Review Body 
(AWERB) and associated EU Directive 2010/63/EU for animal experiments. The study was performed on behalf 
of Queen’s University Belfast (QUB) by the Veterinary Sciences Division, Agri-Food and Biosciences Institute, 
Belfast, Northern Ireland. Sixteen pigs, eight control and eight treated (a cross of Large White and Landrace 
breeds, PIC 337 breed), each identified by an ear tag were used in the study.
www.nature.com/scientificreports/
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Housing. During the study, pigs were housed in individual pens in sight of the other pigs. The individual pens 
were made of chain link; sawdust/wood shavings prevented the animals from slipping and provided a substance 
in which the pigs could root. In addition chains were supplied as toys for the animals. The pens met the require-
ments of EC/2010/63 Directive regarding animal welfare.
Diet. Pigs were fed once a day with all groups supplied with the same quantity of food/day, determined by the 
body weight of the control group, with the daily food intake of each pig recorded throughout the study. The diet 
was based on the breeder’s recommendations and free access to water was provided by an automated watering 
system.
Treatment. Following the acclimatization period of seven days, eight healthy pigs were selected randomly for 
the control group and the remaining eight healthy pigs assigned to the treatment group. Before treatment, animals 
were examined by a veterinarian to confirm clinical health and then weighed, with the weight and identification 
of animals in each group recorded. Over the study period (13 weeks), each animal from the treatment group 
received a low dose of MC-LR daily by oral gavage. The dose administered was 0.04 µg toxin/kg body weight, the 
provisional World Health Organization Tolerable Daily Intake (WHO TDI), based on the NOAEL derived from 
the animal experiment conducted by Fawell et al. (1999), with the average dose for the eight treated animals out-
lined in Table 3. Briefly, a 1 mg/mL solution of MC-LR was prepared by the addition of 250 µL of ethanol followed 
by 750 µL water. The appropriate dilutions were then performed depending on the weight of the animal to ensure 
the correct dose was administered in 5 mL of water.
Serum was collected weekly, starting at day -7 from treated and control animals as the pre-bleeds. Serum 
samples were collected using a Vacutainer system with all samples processed as quickly as possible and the serum 
stored at −80 °C prior to use. At day 97 (approximately 13 weeks) treated and control animals were euthanized 
by intravenous barbiturate and the pigs exsanguinated by jugular severance. Liver, kidney, spleen, large and small 
intestines and brain samples were collected for MC-LR toxin content and stored at −20 °C. All samples were 
labelled with the date and time of sampling, the animal identification and whether it was from the treated or 
control group.
Animal Study 2. This study was performed as described previously using twelve male Duroc pigs, six control 
and six treated pigs. Housing, diet and treatment were as described previously with the following modifications:
Animals were subjected to a fourteen-day acclimatization period prior to assignment to control or treated 
groups. Over the study period, each animal from the treatment group received a daily dose of 2 µg toxin/kg body 
weight MC-LR by oral gavage, 50 times the provisional WHO TDI, with the average dose for the six treated 
animals outlined in Table 4, with the MC-LR for dosing prepared as described above. At day 40 (approximately 
5 weeks) treated and control animals were euthanized. Sample collection and storage was as outlined for exper-
iment 1.
Materials. Microcystin-LR (MC-LR) and nodularin (NOD) standards were purchased from Enzo Life 
Sciences (UK) Ltd and 2-Methoxy-4-phenylbutyric acid (MMPB) was purchased from Wako Pure Chemical 
Industries Ltd (Japan). All other chemicals used were purchased from Sigma Aldrich, UK, bar the OASIS HLB 
and OASIS PRiME HLB solid phase extraction (SPE) cartridges (60 mg, 3 cc) which were purchased from Waters, 
Ireland. The water used was supplied from an in-house 18 MΏ Millipore water system, Millipore (UK) Ltd.
Standards of MC-LR, NOD (IS) and MMPB used for method development, validation and sample analysis 
were prepared as outlined in the Supplementary Information online.
Extraction of free MC-LR from porcine serum. Serum samples (see Supplementary Information online) 
(250 µL) were spiked with 15 µL of the NOD (IS) at 0.5 µg/mL and extracted by addition of 1.8 mL 80% aqueous 
methanol (v/v) (0.5% acetic acid v/v), vortex mixed briefly and sonicated for 45 min before centrifugation at 16 
000 g for 15 minutes. The supernatant was removed and diluted approximately five-fold by addition of water to 
reduce the methanol content to 15% (v/v) for loading onto SPE cartridges. Samples were loaded onto the OASIS 
HLB cartridges and allowed to drip through under gravity, after which cartridges were washed with water and 
20% aqueous methanol (v/v). Bound toxin was eluted into clean glass tubes with 2 × 1.5 mL 80% aqueous meth-
anol (v/v) containing 0.1% trifluoroacetic acid (v/v). The resulting eluents were evaporated to dryness under a 
Wk 
1
Wk 
2
Wk 
3
Wk 
4
Wk 
5
Wk 
6
Wk 
7
Wk 
8
Wk 
9
Wk 
10
Wk 
11
Wk 
12 End*
Average weight of pig (kg) 20 28 36 44 52 60 68 76 84 92 100 108 116
Average MC-LR Dose/day (µg) 0.8 1.1 1.4 1.8 2.1 2.4 2.7 3.0 3.4 3.7 4.0 4.3 n/a
Total Dose per week (µg) 5.6 7.8 10.1 12.3 14.6 16.8 19.0 21.3 23.5 25.8 28.0 30.2 n/a
Table 3. Average weight of the eight treated animals for each week of experiment 1 (low dose). Table indicates 
the average dose administered daily and weekly based on this weight and the average overall dose administered 
over the course of experiment (1), dosed at 0.04 µg/kg bodyweight (bw). Average Total Dose = 215.0 µg. 
*Average weight of pigs at the end of the experiments before being euthanized.
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gentle stream of nitrogen using a turbovap at 50 °C. Dried samples were reconstituted in 50 µL 80% aqueous 
methanol (v/v) and transferred to a micro vial for analysis.
Extraction of free MC-LR and MC-LR-GSH from porcine tissues. Tissue samples (see Supplementary 
Information online) (100 mg) were spiked with 10 μL of the NOD (IS) at 0.5 μg/mL and extracted by addition of 
1.5 mL of 80% aqueous MeOH (v/v) (0.5% acetic acid v/v), vortex mixed briefly and sonicated at 35–40 °C for 
45 min before centrifugation at 16 000 g for 15 min. Clean-up was performed as described above with the samples 
reconstituted in 200 µL 80% aqueous methanol (v/v) and transferred to micro vials for analysis.
Lemieux oxidation and extraction of MMPB. Porcine tissue samples (50 mg) were weighed into 50 mL 
round bottomed flasks with the conversion and subsequent enrichment of MMPB carried out as outlined in 
‘Analysis of conjugated MC-LR in porcine tissue’ (see Supplementary Information online). Samples were initially 
screened for MMPB, with any samples found to contain toxin quantified by use of a six point extracted matrix 
matched calibration curve in the range 0.010–0.25 µg/g dw using pooled control tissue of the relevant tissue, with 
calibrant levels achieved by spiking with the MMPB standard at a concentration of either 0.5 or 0.05 µg/mL after 
pH adjustment.
Ultra-performance liquid chromatography tandem mass spectrometry (UPLC- MS/MS). 
Analysis of free MC-LR in porcine serum. Analysis was performed using an ACQUITY UPLC i-Class system 
coupled to a Xevo TQ-S (triple quadrupole MS/MS) Mass Spectrometer (Waters, Manchester, UK). Detection and 
quantification was achieved using targeted analysis using Multiple Reaction Monitoring (MRM) and operated in 
ESI+ mode. Analyte precursor ions were identified as [M + H]+ for both MC-LR and NOD (IS) with the quanti-
fying (Q) and qualifying (q) ions used as follows:
MC-LR: 995.6 > 135.03 (Q) and 995.6 > 107.05 (q)
NOD (IS): 825.5 > 135.0*
*Only one transition required due to it being used as an internal standard (IS).
Separation was achieved using an ACQUITY UPLC BEH C18 column, 50 mm × 2.1 mm i.d., 1.8 µm particle 
size, 130 Å pore size, (Waters, UK) with the column maintained at 45 °C. The mobile phases comprised water 
(0.1% acetic acid v/v) and acetonitrile (ACN) with the flow rate set at 0.45 ml/min. The gradient used to achieve 
separation consisted of ACN held initially at 2% for 0.5 minute, followed by an increase to 80% over 4 min, washed 
for 1 min at 90% before returning to 2% for a 1 min re-equilibration time before the next sample injection of 
2.5 µL.
Analysis of free MC-LR, bound MC-LR (MMPB) and MC-LR-GSH in porcine tissues. For the methodology of the 
analysis of MC-LR, free and bound, MC-LR-GSH and NOD (IS), see Supplementary Information.
Ethics. The animal studies were performed in accordance with a licence issued by the Department of Health, 
Social Services and Public Safety in NI under the animals (scientific procedures) act 1986 and under the approval 
of the approval of the Agri-Food and Biosciences Institute (AFBI) Animal Welfare and Ethical Review Body 
(AWERB), and associated EU Directive 2010/63/EU for animal experiments. The project license is PPL 2755 for 
chemical contaminants in food producing animals.
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